Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.
about
Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice.Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities studyGlycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson diseaseA systems biology investigation of neurodegenerative dementia reveals a pivotal role of autophagy.Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndromeSmall-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease ModelsDiscovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's diseaseGlycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis.Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3.RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity.Recent progress in neuroactive marine natural products.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.GSK-3β, a pivotal kinase in Alzheimer disease.Selective growth inhibition by glycogen synthase kinase-3 inhibitors in tumorigenic HeLa hybrid cells is mediated through NF-κB-dependent GLUT3 expression.Preferential selectivity of inhibitors with human tau protein kinase gsk3β elucidates their potential roles for off-target Alzheimer's therapy.Steroid and Xenobiotic Receptor Signalling in Apoptosis and Autophagy of the Nervous System.Learning ability is a key outcome determinant of GSK-3 inhibition on visuospatial memory in rats.Peripheral Administration of GSK-3β Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer's Disease.Genetics pathway-based imaging approaches in Chinese Han population with Alzheimer's disease risk.Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease.Protective effects of Phyllanthus emblica against myocardial ischemia-reperfusion injury: the role of PI3-kinase/glycogen synthase kinase 3β/β-catenin pathway.Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
P2860
Q30362847-016204C5-61B1-4D18-A999-83F6091E726AQ33566835-9FE96CB7-78D7-41F1-9A39-8BB2D1A68111Q34591684-DDF88AA1-75F1-4215-AA94-001D32603C36Q35183471-DF951B3C-173A-4912-AEF5-8D1748001074Q35492486-CDB5A209-1B99-4888-A086-C574FD4A5D95Q36128825-68C0EA57-C96F-4D72-AAD6-4B683545EF11Q36329594-2AF60FB3-2F2D-4257-B27A-DDDD23759FCDQ36415259-611C7827-F516-4281-8E79-1E3073D3303DQ36720075-3B2D1DAE-C4BB-4348-9254-D6A9667E4269Q36850239-FAD14ADE-A5E5-4DE9-AF06-FBEFD691CE4BQ36863419-341E5406-9AEF-425D-A68C-0FF75B331556Q37315215-B358986F-106A-4983-9CD2-264056080154Q37639029-93642F95-5D72-4707-B951-BBB4F06478D6Q38126701-7CD3F468-CEB9-420E-B5F9-E3FBB04C24C1Q38218085-9636B7FD-3280-4211-9B96-C4EFE3719AA8Q41975361-975FDB08-B885-4943-9195-72CCE3CEAB7EQ42263333-A46CFABE-4EE6-4C4C-9E29-A8CC8F337D80Q47129713-03E18A2B-C859-4F3D-B6C6-1C64A7B5EE95Q47736903-6105DD19-0EAC-4579-99EB-06773CB9AD7BQ48469041-78BCBB79-70A5-4E87-AF80-D2BA67BE5DD6Q48475670-6466F0BB-DCF4-4403-BA91-061A79903622Q50130748-84FCCD1D-036F-4B03-844C-11BD4EC1D3BAQ53355500-D1BC323D-B2F7-4AA8-B70E-C46A8D34E2A3Q58539506-EDF4051A-899B-4C6F-95A0-E2541379B57CQ58696563-ED475893-A372-4D9D-8636-A1964C838F5D
P2860
Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Glycogen synthase kinase 3 inh ...... Alzheimer's disease treatment.
@en
Glycogen synthase kinase 3 inh ...... Alzheimer's disease treatment.
@nl
type
label
Glycogen synthase kinase 3 inh ...... Alzheimer's disease treatment.
@en
Glycogen synthase kinase 3 inh ...... Alzheimer's disease treatment.
@nl
prefLabel
Glycogen synthase kinase 3 inh ...... Alzheimer's disease treatment.
@en
Glycogen synthase kinase 3 inh ...... Alzheimer's disease treatment.
@nl
P2860
P50
P356
P1476
Glycogen synthase kinase 3 inh ...... Alzheimer's disease treatment.
@en
P2860
P304
P356
10.4061/2011/280502
P577
2011-06-30T00:00:00Z